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Abstract Obesity is a major health problem in industrialized
societies often associated with diabetes, insulin resistance,
and hepatic steatosis. This review addresses the hypothesis
that elongation of long-chain fatty acids family member 6
(Elovl6) has an important role in energy metabolism and
insulin sensitivity. Elovl6 is a microsomal enzyme involved
in the elongation of saturated and monounsaturated fatty
acids with 12, 14, and 16 carbons. Mice with targeted
disruption in the gene for Elovl6 (Elovl6−/−) are resistant to
diet-induced insulin resistance despite their hepatosteatosis
and obesity being similar to that of the wild-type mice.
Protection against diet-induced insulin resistance in Elovl6–/–
mice is partially due to restoration of hepatic insulin receptor
substrate-2 and suppression of hepatic protein kinase C ɛ,
resulting in restoration of Akt phosphorylation. We suggest
that inhibition of this elongase could be a new therapeutic
approach for the treatment of insulin resistance, diabetes,
cardiovascular disease, and other metabolic diseases.
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Introduction
Insulin resistance, a state of reduced responsiveness to
insulin, is associated with obesity and is the major
pathogenic indicator of obesity-related diseases. Although
major advances have been made in unraveling the under-
lying defects that cause insulin resistance, many of the
pathways and regulators that connect insulin to its
downstream metabolic effects are not fully understood.
Epidemiological studies have demonstrated that intake of
excess carbohydrate and saturated fatty acids results in
accumulation of lipid, promoting a lipotoxic state, and
evokes insulin resistance in the skeletal muscle, adipose
tissue, and liver leading to obesity-related diseases, includ-
ing the metabolic syndrome [1, 2] highlighting the
importance of lipid accumulation in the pathogenesis.
Previous studies on acetyl-coenzyme A (CoA) carboxylase,
fatty acid synthase (FAS), and stearoyl-CoA desaturase 1
(SCD-1) indicate that endogenous fatty acid synthesis is
also crucial for energy metabolism and insulin sensitivity in
the liver [3–6]. Recently, we have shown that inhibition of
another key lipogenic enzyme, Elovl6, which elongates
long-chain saturated and unsaturated fatty acids can
modulate insulin resistance in fatty livers, even with
concurrent obesity [7]. In this review, we propose the
hypothesis that preventing the formation of very long-chain
fatty acids and manipulating the fatty acid composition by
blocking this enzyme could protect against insulin resis-
tance and obesity-related disorders, and discuss the molec-
ular mechanism of this new paradigm.
Expression and regulation of the Elovl6 gene
Elovl6 belongs to a highly conserved family of endoplasmic
reticulum enzymes involved in the formation of long-chain
fatty acids [8, 9]. Functional analysis using expression
experiments in cultured cells demonstrated that this enzyme
specifically catalyzes the elongation of saturated and
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monounsaturated fatty acids with 12, 14, and 16 carbons,
and was the last piece of the puzzle in enzymes responsible
for endogenous fatty acid synthesis [10, 11]. In mice, Elovl6
is expressed at a high level in the adrenal gland, liver, white
adipose tissue, brown adipose tissue, brain, testis, and skin,
where lipogenesis and steroidogenesis are active [10, 11].
Hepatic expression of the Elovl6 gene is consistently
activated in the liver of transgenic mice overexpressing
nuclear sterol regulatory element-binding protein (SREBP)-
1a, -1c, or -2 [10, 11]. Elovl6 mRNA levels in the liver and
adipose tissue markedly elevated in a refed state after fasting
[11]. Dietary polyunsaturated fatty acids cause a profound
suppression of Elovl6 expression [11]. Hepatic Elovl6
expression is also highly up-regulated in leptin-deficient
ob/ob mice [11]. Thus, this elongase is a new member of the
mammalian lipogenic enzymes regulated by SREBP-1,
playing an important role in de novo synthesis of long-
chain saturated and monounsaturated fatty acids in conjunc-
tion with FAS and SCD-1 (Fig. 1). Promoter analysis of
mouse Elovl6 identified two SREBP-binding sites: proximal
SRE-1 and distal SRE-2, and Elovl6 is regulated directly and
primarily by SREBP-1c [12].
Role of Elovl6 in the development of diet-induced insulin
resistance Studies on Elovl6−/− mice showed that loss of
Elovl6 function increased levels of palmitate (C16:0) and
palmitoleate (C16:1n−7), but reduced levels of stearate
(C18:0) and oleate (C18:1n−9), confirming that Elovl6
catalyzes the chain elongation of palmitate to stearate and
the elongation of palmitoleate to vaccinate (C18:1n−7) in
vivo [7].
Apart from dramatic alterations in fatty acid composi-
tion, the Elovl6−/− mice do not differ from wild-type
littermates in case of overall lipid concentration of the liver
and plasma. The Elovl6−/− mice appear grossly normal
although slightly leaner than their wild-type littermates.
Postprandial plasma levels of insulin and leptin are lower in
the Elovl6−/− than that in the wild-type mice, while no
significant changes are observed in plasma glucose or lipid
levels.
On a high-fat, high sucrose (HF-HS) diet, the wild-type
and Elovl6−/− mice gain body weight and total body fat
percentage at similar rates at identical daily food intake.
The Elovl6−/− mice have a greater tendency to suffer from
severe hepatosteatosis than the wild-type mice, as estimated
by hepatic triglycerides and cholesterol. In response to
diet-induced obesity, the wild-type mice exhibited a robust
elevation in plasma insulin levels accompanied by a slight
increase in plasma glucose, indicating the emergence of
insulin resistance. However, the Elovl6−/− mice showed a
significant reduction in plasma insulin levels compared to
the wild-type mice. Insulin sensitivity, as measured by
reduction in plasma glucose levels after insulin adminis-
tration, was markedly reduced in the wild-type mice with
an HF-HS diet, whereas the Elovl6−/− mice showed a
nearly normal response to insulin. Thus, Elovl6−/− mice
are resistant to diet-induced insulin resistance, despite
their hepatosteatosis and obesity being similar to that of
the wild-type mice.
Elovl6 deficiency restores suppressed Akt phosphoryla-
tion in the liver, but not in the skeletal muscle and white
adipose tissue. Thus, amelioration of whole-body insulin
Fig. 1 Role of Elovl6 in mam-
malian fatty acid synthesis and
changes of the fatty acid compo-
sition by the Elovl6 deficiency.
ACC acetyl-CoA carboxylase,
FAS fatty acid synthase, ER
endoplasmic reticulum, SCD-1
stearoyl-CoA desaturase-1
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resistance in the Elovl6−/− mice can be attributed to the
restoration of hepatic insulin sensitivity. Restoration of Akt
phosphorylation is accompanied by increased total and
phosphorylated insulin receptor substrate (IRS)-2 protein in
the livers of the Elovl6−/− mice, whereas phosphorylated
insulin receptor and IRS-1 remain suppressed by an HF-HS
diet in both genotypes, demonstrating that restoration of
insulin signaling is mediated by recovery of the hepatic
IRS-2/Akt signaling pathway in Elovl6−/− mice (Fig. 2).
Several lines of evidence suggest that lipid metabolites,
such as acyl-CoAs, diacylglycerol (DAG), and ceramides,
rather than triglycerides themselves, are the determinants of
the development of insulin resistance accompanying the
accumulation of intracellular lipids [13–15]. DAG accumu-
lation has been reported to be linked to increased protein
kinase C epsilon (PKCɛ) activity and impaired phosphor-
ylation of insulin receptor, IRS-1, and IRS-2 tyrosine by
insulin [13, 14]. In the wild-type mice, hepatic DAG
content and PKCɛ activity are significantly increased in the
liver in response to an HF-HS diet. However, the livers of
Elovl6−/− mice contain less DAG and show lower expres-
sion of PKC compared with the wild-type mice, indicating
that protection against diet-induced insulin resistance in the
Elovl6−/− mice might be mediated, at least partially, through
the DAG/PKCɛ pathway (Fig. 2).
Role of Elovl6 in regulation of lipogenesis and fatty acid
oxidation
In the livers of Elovl6−/− mice, how would energy
metabolism change with changes in fatty acid composition?
An HF-HS diet augmented the hepatic expression of
SREBP-1c itself and its target lipogenic enzyme genes,
including genes for FAS, Elovl6, SCD-1, and GPAT, in the
wild-type mice. The dietary induction of these lipogenic
genes is suppressed in the Elovl6−/− mice [7]. As we
have previously reported, activation of SREBP-1c direct-
ly represses IRS-2, the main insulin signal mediator, and
causes hepatic insulin resistance [16]. Therefore, sup-
pression of SREBP-1c can contribute to the amelioration
of hepatic insulin resistance in the Elovl6−/− mice.
Consistent with this notion, IRS-2 expression, which is
completely suppressed by an HF-HS diet in the wild-type
mice, is restored in the liver of Elovl6−/− mice (Fig. 2).
Meanwhile, genes related to fatty acid oxidation that are
regulated by nuclear receptor PPARα, such as carnitine
palmitoyltransferase-1, medium-chain acyl-CoA dehy-
drogenase, acyl-CoA oxidase, and cytochrome P450
4a14, are induced by an HF-HS diet in the wild-type
mice. However, these oxidation genes, including PPARα,
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Fig. 2 Absence of Elovl6 improves hepatic insulin sensitivity without
amelioration of obesity and hepatosteatosis. Elovl6 deficiency alters
hepatic fatty acid composition; changes in fatty acid chain length
(decrease in long-chain fatty acids more than C18) and the ratio of
fatty acids (C18:0/C16:0, C16:1/C16:0) could reduce SREBP-1 and
PPARα in the liver. Reduction in SREBP-1 leads to decreased fatty
acid synthesis via reduction of lipogenic gene expression and
increases in IRS-2 level and insulin sensitivity. Reduction in
lipogenesis could lead to decreased hepatic diacylglycerol content,
which would lead to decreased PKCɛ activity and increased insulin
sensitivity. Unknown mechanisms might include changes in lipid
signaling and protein fatty acylation that could improve insulin
signaling
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contrast to the amelioration of insulin resistance. Thus,
Elovl6 deficiency leads to suppression of both synthesis
and degradation of fatty acids by affecting SREBP-1c and
PPARα expression (Fig. 2). The signals generated in the
Elovl6−/− mice that lead to reduced SREBP-1c and
PPARα expression and consequent reduction in lipid
metabolism and increase in insulin sensitivity are cur-
rently being studied.
Function of other Elovl enzymes
Elovl family is composed of seven distinct fatty acid
elongase subtypes (Elovl1-7) that are present in the mouse,
rat, and human genomes. Each elongase has a distinct tissue
distribution, and individual enzymes exhibits different fatty
acid substrate preferences [8, 9, 17, 18]. Elovl1 (Ssc1)
catalyze the condensation of a broad array of saturated and
monounsaturated fatty acids up to C24 [19]. Elovl2 (Ssc2)
substrates include C20 and C22 PUFAs [19]. Elovl3
(Cig30) and Elovl4 elongate different fatty acids ≤C26
[20, 21]. Elovl5 is involved in the elongation of various
PUFAs of C18 and C20 [22]. Elovl7 has not been well
characterized. In contrast to other elongases, Elovl6
expression is regulated by many dietary, hormonal, and
developmental factors [11, 17, 18]. Consistent with this,
Elovl6 is only elongase to connecting with de novo
lipogenesis.
Deletion of the gene coding for Elovl enzymes in mice
were reported in Elovl3, Elovl4, Elovl5 as well as Elovl6.
Elovl3-null mice displayed a sparse hair coat, the hyper-
plasia of the sebaceous glands, and increased transepider-
mal water loss in a water barrier function test due to the
decreased level of C22–24 saturated and monounsaturated
fatty acids with exceptionally high levels of eicosenoic acid
(C20:1) in hair lipids [23]. Elovl4−/− mice displayed
profound skin atrophy and impaired water insulation
function due to lacking ceramides with 5-hydroxy very
long-chain fatty acids (≥C28) [24, 25]. Elovl5−/− mice
demonstrated that decreased elongation of C18:3n−6 to
C20:3n−6 and C18:4n−3 to C20:4n−3 and that the
decreased cellular arachidonic acid (20:4n−6) and DHA
(22:6n−3) concentrations de-represses the activation of
SREBP-1c and its target genes involved in fatty acid and
triglyceride synthesis, which resulted in the development of
hepatic steatosis [26]. It was also reported that adenoviral-
mediated induction of Elovl5 activity in livers of mice
increased hepatic and plasma levels of 20:3n−6 while
suppressing hepatic arachidonic acid (20:4n−6) and DHA
(22:6n−3) content. Such alterations in fatty acid profile
affect the expression of PPARα-regulated genes and hepatic
glucose production during fasting [27]. Elovl5 is abundant
in the liver, and the gene expression is controlled by
SREBP-1 and PPARα. Examination of the relations
between hepatic Elovl5 activity and energy metabolism
should provide new findings for the treatment of metabolic
disease. These observations suggest that Elovl6 and
possibly Elovl5 are involved in central energy metabolism,
whereas other Elovl enzymes are involved in regulation of
longer and polyunsaturated fatty acids, which is crucial for
lipid metabolism in peripheral tissues like skin. Alterations
in fatty acid profile as a consequence of Elovl gene
deletion, as those seen in Elovl3, Elovl4, Elovl5, and Elovl6
mutant mice, emphasize the importance of these enzymes in
maintaining fatty acid homeostasis for proper cellular
function and energy metabolism.
New aspects of fatty acid synthesis and insulin resistance
Palmitate has long been thought to be the major detrimental
fatty acid in insulin resistance [1]. In the Elovl6−/− mice,
however, the palmitate levels are increased, but insulin
sensitivity is maintained, suggesting that it is the hepatic
fatty acid composition, particularly the conversion of
palmitate to stearate, which is crucial for insulin sensitivity
than simply the accumulation of palmitate.
Recently, Cao et al. reported that the palmitoleate
(C16:1n−7) is an important signaling lipid hormone newly
designated as a “lipokine,” stimulating activity of muscle
insulin action and influencing fat deposition in the liver
[28]. Utilizing quantitative lipidomic analysis, they found
that mice lacking FABP4 and FABP5, exhibiting a
striking phenotype with strong protection from diet-
induced obesity, insulin resistance, and fatty liver disease
[29], has a fourfold higher concentration of palmitoleate
in plasma, compared to wild-type mice on high-fat diet.
The adipose tissue-derived palmitoleate travels to the
muscle cells and liver, where it improves cell sensitivity to
insulin in muscle and blocks fat accumulation in the liver.
Intriguingly, our data from Elovl6−/− mice also highlights
palmitoleate as a fatty acid potentially responsible for
sustained insulin sensitivity. Elovl6−/− mice increased
liver and, resultantly, plasma palmitoleate level, but
skeletal muscle insulin sensitivity and hepatic triglyceride
content did not altered, questioning that this particular
fatty acid in circulation can simply modify peripheral
tissue insulin sensitivity. The precise molecular mecha-
nism that palmitoleate promotes the insulin sensitivity in
liver and muscle is yet to be clarified. Further studies of
the mice deficient in fatty acids such as FABP, Elovl6, and
SCD1 are important for the clarification of this molecular
mechanism.
SCD catalyzes the conversion of stearate, the end
product of Elovl6, to oleate, the final product of endoge-
nous lipogenesis. The similarity of SCD1 and Elovl6 in ER
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localization, gene structures, and the coordinating functions
of both proteins implicates that these genes could be
derived from a common ancestral gene. Inhibition of
SCD1 expression caused by Elovl6 deficiency was prom-
inent in mice both normal and HF-HS diet [7]. Mice with
global knockout of SCD1 (SCD1−/− mice) show decreased
lipogenic gene expression and increased β-oxidation and
are protected from diet-induced obesity, hepatic steatosis,
and insulin resistance [5]. Liver-specific SCD1 knockout
(LKO) mice are protected from high-sucrose, very low-fat
diet-induced obesity and hepatic steatosis because of the
decreased lipogenic gene expression without the change in
the fatty acid β-oxidation gene expression [6]. It is possible
that the decrease in SCD1 expression could partly contrib-
ute to the insulin-sensitizing effect of Elovl6 deficiency.
However, in contrast to SCD1−/− and LKO mice, Elovl6−/−
mice showed sustained obesity, hepatic steatosis, and low
fatty acid oxidation in liver, indicating that the mechanisms
by which these two enzymes influence insulin sensitivity
are not completely convergent.
Amelioration of insulin resistance in obese mice is
usually accompanied by loss of fat or body weight caused
by decreased food intake, enhanced lipid oxidation, and/or
decreased lipogenesis [5, 30–32]. Elovl6−/− mice are unique
in that their insulin resistance is improved without
amelioration of obesity or hepatosteatosis. These data
highlight the importance of tissue fatty acid composition
in insulin sensitivity, especially the ratio of C18 to C16
acids, which is controlled by Elovl6 activity. The precise
molecular mechanism for this is currently unknown.
Distinct effects of different long fatty acids depending
upon their extent of desaturation have been generally
observed. However, our current studies suggest that the
length of fatty acids is also important in energy metabo-
lism and insulin sensitivity. This model aids our under-
standing of the mechanism by which obesity and obesity-
related disorders are sometimes dissociated, and these
observations could lead to new therapeutic strategies for
diabetes and cardiovascular diseases that target elongase
enzymes.
For the treatment and prevention of obesity-related
disorders, control of the quantity of lipid accumulating in
tissue and blood is important, and thus diet has been the
main target. Together with beneficial roles of some pieces
of PUFA, the lessons from Elovl6−/− mice suggest that
quality aspect of lipids should be more focused for future
strategy against cardiovascular diseases.
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